Apontis Pharma AG

XETRA APPH.DE

Apontis Pharma AG Price to Earnings Ratio (P/E) on February 05, 2025: -7.87

Apontis Pharma AG Price to Earnings Ratio (P/E) is -7.87 on February 05, 2025, a -97.06% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Apontis Pharma AG 52-week high Price to Earnings Ratio (P/E) is -4.14 on February 09, 2024, which is 47.32% above the current Price to Earnings Ratio (P/E).
  • Apontis Pharma AG 52-week low Price to Earnings Ratio (P/E) is -7.87 on February 05, 2025, which is 0.00% below the current Price to Earnings Ratio (P/E).
  • Apontis Pharma AG average Price to Earnings Ratio (P/E) for the last 52 weeks is -6.09.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
SV Wall Street
XETRA: APPH.DE

Apontis Pharma AG

CEO Mr. Bruno Wohlschlegel
IPO Date May 11, 2021
Location Germany
Headquarters Alfred-Nobel-Str. 10
Employees 177
Sector Healthcare
Industries
Pharmaceuticals Drugstores & Retail Pharmacies
Description

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.

StockViz Staff

February 6, 2025

Any question? Send us an email